These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 16172459)

  • 1. Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck.
    Wirth LJ; Haddad RI; Lindeman NI; Zhao X; Lee JC; Joshi VA; Norris CM; Posner MR
    J Clin Oncol; 2005 Oct; 23(28):6976-81. PubMed ID: 16172459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Cohen EE; Kane MA; List MA; Brockstein BE; Mehrotra B; Huo D; Mauer AM; Pierce C; Dekker A; Vokes EE
    Clin Cancer Res; 2005 Dec; 11(23):8418-24. PubMed ID: 16322304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer.
    Reckamp KL; Krysan K; Morrow JD; Milne GL; Newman RA; Tucker C; Elashoff RM; Dubinett SM; Figlin RA
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3381-8. PubMed ID: 16740761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of docetaxel-induced cytotoxicity by blocking epidermal growth factor receptor and cyclooxygenase-2 pathways in squamous cell carcinoma of the head and neck.
    Choe MS; Chen Z; Klass CM; Zhang X; Shin DM
    Clin Cancer Res; 2007 May; 13(10):3015-23. PubMed ID: 17505004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of gefitinib in combination with radiation or chemoradiation for patients with locally advanced squamous cell head and neck cancer.
    Chen C; Kane M; Song J; Campana J; Raben A; Hu K; Harrison L; Quon H; Dancey J; Baron A; Said S; Eckhardt SG; Raben D
    J Clin Oncol; 2007 Nov; 25(31):4880-6. PubMed ID: 17971583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck.
    Cohen EE; Rosen F; Stadler WM; Recant W; Stenson K; Huo D; Vokes EE
    J Clin Oncol; 2003 May; 21(10):1980-7. PubMed ID: 12743152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck.
    Hussain M; Gadgeel S; Kucuk O; Du W; Salwen W; Ensley J
    Cancer; 1999 Dec; 86(11):2364-9. PubMed ID: 10590379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 1 trial of concurrent erlotinib, celecoxib, and reirradiation for recurrent head and neck cancer.
    Kao J; Genden EM; Chen CT; Rivera M; Tong CC; Misiukiewicz K; Gupta V; Gurudutt V; Teng M; Packer SH
    Cancer; 2011 Jul; 117(14):3173-81. PubMed ID: 21246519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected].
    Stewart JS; Cohen EE; Licitra L; Van Herpen CM; Khorprasert C; Soulieres D; Vodvarka P; Rischin D; Garin AM; Hirsch FR; Varella-Garcia M; Ghiorghiu S; Hargreaves L; Armour A; Speake G; Swaisland A; Vokes EE
    J Clin Oncol; 2009 Apr; 27(11):1864-71. PubMed ID: 19289630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase I/II trial of concurrent docetaxel and radiation after induction chemotherapy in patients with poor prognosis squamous cell carcinoma of the head and neck.
    Tishler RB; Norris CM; Colevas AD; Lamb CC; Karp D; Busse PM; Nixon A; Frankenthaler R; Lake-Willcutt B; Costello R; Case M; Posner MR
    Cancer; 2002 Oct; 95(7):1472-81. PubMed ID: 12237916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck.
    Baselga J; Trigo JM; Bourhis J; Tortochaux J; Cortés-Funes H; Hitt R; Gascón P; Amellal N; Harstrick A; Eckardt A
    J Clin Oncol; 2005 Aug; 23(24):5568-77. PubMed ID: 16009950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck.
    Herbst RS; Arquette M; Shin DM; Dicke K; Vokes EE; Azarnia N; Hong WK; Kies MS
    J Clin Oncol; 2005 Aug; 23(24):5578-87. PubMed ID: 16009949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study.
    Siu LL; Soulieres D; Chen EX; Pond GR; Chin SF; Francis P; Harvey L; Klein M; Zhang W; Dancey J; Eisenhauer EA; Winquist E; ;
    J Clin Oncol; 2007 Jun; 25(16):2178-83. PubMed ID: 17538162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma.
    Reardon DA; Quinn JA; Vredenburgh JJ; Gururangan S; Friedman AH; Desjardins A; Sathornsumetee S; Herndon JE; Dowell JM; McLendon RE; Provenzale JM; Sampson JH; Smith RP; Swaisland AJ; Ochs JS; Lyons P; Tourt-Uhlig S; Bigner DD; Friedman HS; Rich JN
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):860-8. PubMed ID: 16467100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic chemotherapy with cisplatin plus 5-FU (PF) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): efficacy and safety of a lower dose of PF (80/800) at a single institution in Japan.
    Kiyota N; Tahara M; Kadowaki S; Fuse N; Doi T; Minami H; Ohtsu A
    Jpn J Clin Oncol; 2009 Apr; 39(4):225-30. PubMed ID: 19211574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
    Suntharalingam M; Jaboin J; Taylor R; Wolf J; Banglore M; Van Echo D; Ord R
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):2-7. PubMed ID: 15726515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective randomized phase II study comparing metronomic chemotherapy with chemotherapy (single agent cisplatin), in patients with metastatic, relapsed or inoperable squamous cell carcinoma of head and neck.
    Patil VM; Noronha V; Joshi A; Muddu VK; Dhumal S; Bhosale B; Arya S; Juvekar S; Banavali S; D'Cruz A; Bhattacharjee A; Prabhash K
    Oral Oncol; 2015 Mar; 51(3):279-86. PubMed ID: 25578869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of paclitaxel, ifosfamide, and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
    Shin DM; Glisson BS; Khuri FR; Hong WK; Lippman SM
    Semin Oncol; 1998 Apr; 25(2 Suppl 4):40-4; discussion 45-8. PubMed ID: 9578061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in paclitaxel-containing chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck.
    Shin DM; Glisson BS; Khuri FR; Ginsberg L; Lawhorn K; Hong WK; Lippman SM
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-33-S19-37. PubMed ID: 9427263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: a preliminary report.
    Hussain M; Salwen W; Kucuk O; Ensley J
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-43-S19-45. PubMed ID: 9427265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.